CutPRO Cut Resistant Clothing 2020 Collection Intends To Eliminate Laceration In The Glass Industry
24.9.2019 17:00:00 EEST | Business Wire | Press release
British cut resistant clothing brand CutPRO is determined to help glass producers around the globe to reduce the number and severity of cut injuries and lacerations. The company’s ultimate objective is to eliminate such injuries in the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190924005600/en/
Latest CutPRO design following global consultations (Photo: Business Wire)
Officially announcing its 2020 product range today, CutPRO is extremely proud to have established close relationships with some of the world’s largest producers of float and high-performance glass.
These relationships have resulted in new and improved garment designs, which reflect the information gathered. Customer feedback, extended research into potential risks and a clearer understanding of the precise work environment have proven invaluable.
CutPRO senior product consultants have visited several plants and locations, met with senior health & safety officials and spoken to many glass workers, allowing each one to have an input.
Fully understanding that cut resistant clothing and PPE is mandatory in work environments where cuts and lacerations are a potential risk, the company also wants to ensure the end user is comfortable and excited about wearing the garments.
The temperature variation between the cold end and the hot end of a float glass plant can pose an extreme challenge to comfort and breathability. A factor which turned out to be of greatest importance when designing the latest garments.
As highlighted in the ‘International Labour Organization Encyclopaedia of Occupational Health and Safety’, the main risks for professionals working in the glass manufacturing sector are cuts, lacerations and soft tissues puncture wounds.
According to the ‘International Labour Organization’ about 93% of the lost workday cases in the glass manufacturing sector results from injuries rather than occupational illnesses.
Robert Kaiser, CEO of CutPRO and its parent company PPSS Group says: “We are extremely passionate about reducing the risk of laceration and cut injuries. Our dream is to eliminate cut injuries in the glass industry. We won’t stop until we have achieved precisely that.”
“The handling of flat glass involves the risk of serious personal injury. Accidents continue to happen especially in premises where glass is processed. Appropriate protective clothing should be worn particularly when glass is handled manually, and I strongly believe we can deem CutPRO Cut Resistant Clothing as appropriate.”
All CutPRO garments are fully CE marked and made from the highly acclaimed and thoroughly field-tested Cut-Tex PRO fabric.
#END
About CutPRO®
CutPRO Cut Resistant Clothing is a pioneering brand of highly protective clothing. Made from the world’s most reliable, fully certified and thoroughly field-tested cut resistant fabric Cut-Tex PRO. The company’s social media presence: Facebook, LinkedIn, Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005600/en/
Contact information
Ryan Vickers, Chief Development Officer (CDO)
PPSS Group
info@ppss-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom